The company currently offers target amplification assays for diagnostic use and clinical research that are based on a proprietary multiplex PCR technology.
The firms plan to combine Sophia's DDM software with Multiplicom's molecular diagnostic kits, and sell the solution to European hospitals and laboratories.
The non-invasive test is designed to detect chromosomal abnormalities in the fetus to reduce the number of pregnant women undergoing invasive procedures.
The companies are taking the CE-IVD route as opposed to the LDT model in the US due to Europe's distributed prenatal testing market and lower regulatory hurdles.
NEW YORK (GenomeWeb) – Researchers affiliated with the University of Antwerp and Antwerp University Hospital have partnered with molecular diagnostics firm Multiplicom to develop a test to help identify individuals at risk for sudden cardiac death.
The Associated Press reports that the US Centers for Disease Control and Prevention is beefing up sequencing as a tool to investigate foodborne illnesses.
